A biopharma CEO’s quest for global health equity has put him in the running for a Nobel Prize

Dr. Ryan Saadi, CEO of Tevogen Bio, is making good on a lifelong goal of bringing T cell therapies to people who need them.

By Taren Grom • March 17, 2023

Woman of the Week: Novartis Gene Therapies’ Chris Fox

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...

By Taren Grom • March 15, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

The PharmaVoice 100 — Who makes the cut

What we’re looking for in each new class of honorees.

By Meagan Parrish • March 15, 2023

The power of connections for a startup CEO

Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.

By Alexandra Pecci • March 14, 2023

Babson aims to shed Theranos curse with new blood testing tech

Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?

By Kelly Bilodeau • March 13, 2023

IQVIA’s OG of data analytics on the latest clinical trial trends

IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.

By Taren Grom • March 10, 2023

Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time

Fueled by a fascination with the scientific process, Sindhu Ramchandren is exploring how a new drug could treat patients with a range of rare diseases.

By Michael Gibney • March 9, 2023

While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer

The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.

By Karissa Waddick • March 9, 2023

Targeting the new ‘Golden Girls’

With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

By Taren Grom • March 8, 2023

PharmaVoice 100 honorees: Where are they now?

How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles. 

By Taren Grom , Karissa Waddick • March 3, 2023

The ‘recovering academic’ leading Allogene to the next stage of cell therapy

Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.

By Michael Gibney • March 2, 2023

Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology

With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.

By Taren Grom • March 2, 2023

Do R&D costs justify the price of drugs? Nope, new study says

A BMJ study found that spending on drug sales vastly outstripped spending on drug development.

By Alexandra Pecci • March 1, 2023

As clinical trials face a hiring crunch, here’s how research organizations can pivot

Staffing shortages are causing inefficiencies in clinical trials, but one leading CRO is finding ways to adapt.

By Kelly Bilodeau • Feb. 27, 2023

Cytokinetics looks to muscle into the cardiovascular market

With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.

By Taren Grom • Feb. 24, 2023

Woman of the Week: Alltrna’s Michelle Werner

The first-time CEO has her sights on addressing thousands of diseases with the company’s tRNA platform.

By Taren Grom • Feb. 22, 2023

Tapping into the molecular fountain of youth

Kristen Fortney, CEO of BioAge Labs, wants to improve the human life span by focusing on the human health span.

By Alexandra Pecci • Feb. 22, 2023

Biotechs teeter on unsteady ground in 2023 and some may close shop

A slew of early stage biotechs were forced to shut down last year as the market tanked. Will the trend continue?

By Kelly Bilodeau • Feb. 21, 2023

Why the pharma industry is digging deep in rare disease

The rare disease market is set for major growth in the decade to come, and pharma companies are securing their footholds now.

By Michael Gibney • Feb. 21, 2023

Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies

Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.

By Taren Grom • Feb. 17, 2023

Despite rare disease market growth, pharma leaders see development obstacles ahead

Investment in rare disease research is increasing, but a recent poll of PharmaVoice readers found that roadblocks remain.

By Karissa Waddick • Feb. 17, 2023

Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.

By Michael Gibney • Feb. 16, 2023

Woman of the Week: Bristol Myers Squibb’s Ester Banque

The 30-year veteran is heading up the “transformation” of one of the pharma giant’s most important therapeutic portfolios: hematology.

By Taren Grom • Feb. 15, 2023

Managing for resilience: Passage’s ups and downs in gene therapy

After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.

By Meagan Parrish • Feb. 15, 2023

The post-COVID outlook for decentralized clinical trials

The COVID-19 pandemic had many pharmas turning to DCTs as a way to keep the clinical wheel turning. Can the industry keep that flexibility going forward? 

By Michael Gibney • Feb. 14, 2023